Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        133-144 of 678 results for 'CANCER'

        Refine research

        Research

        A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis

        Here we report that CHAF1B is required for normal hematopoiesis while its overexpression promotes leukemia ...

        Research

        From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress

        Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients alike. Despite advancements in brain cancer research driven by a technological revolution, translating our understanding of glioblastoma pathogenesis into improved clinical outcomes remains a critical unmet need. ...

        Research

        National brain tumour registry: a new era of research collaboration with China

        Cancer continues to be a leading cause of death globally. However, there remains a significant disparity in the reported incidence of cancer in developed countries, estimated to be 295.3 cases per 100,000 people, compared with only 115.7 in developing countries. Some of the reasons for this variation include lack of robust data collection with limited reporting systems, and insufficient data availability in the registries of these developing nations. ...

        Research

        The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program

        Transcriptional cofactors of the ETO family are recurrent fusion partners in acute leukemia. We characterized the ETO2 regulome by integrating transcriptomic and chromatin binding analyses in human erythroleukemia xenografts and controlled ETO2 depletion models. We demonstrate that beyond its well-established repressive activity, ETO2 directly activates transcription of MYB, among other genes. ...

        Research

        Incidence and survival for childhood central nervous system tumours in Australia, 1983–2016

        To investigate incidence and survival of childhood tumours of the central nervous system (CNS) by histological subtype, tumour behaviour and tumour grade. Methods: National, population-based data on all children under 15 years old diagnosed with a CNS tumour between 1983 and 2016 were sourced from the Australian Childhood Cancer Registry. Incidence rate trends were calculated using Joinpoint regression. ...

        Research

        Estimation of quantitative levels of diesel exhaust exposure and the health impact in the contemporary Australian mining industry

        To estimate the levels of exposure to diesel exhaust expressed by EC in the mining industry and to describe the risk of lung cancer that may result from it. ...

        Research

        Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?

        The success of immunotherapy that targets inhibitory T cell receptors for the treatment of multiple cancers has seen the anti-tumor immune response re-emerge as a promising biomarker of response to therapy. Longitudinal characterization of T cells in the tumor microenvironment (TME) helps us understand how to promote effective anti-tumor immunity. However, serial analyses at the tumor site are rarely feasible in clinical practice. ...

        Research

        Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells

        Both tumour suppressive and oncogenic functions have been reported for dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). Herein, we performed a detailed investigation to delineate the role of DYRK1A in glioblastoma. Our phosphoproteomic and mechanistic studies show that DYRK1A induces degradation of cyclin B by phosphorylating CDC23, which is necessary for the function of the anaphase-promoting complex, a ubiquitin ligase that degrades mitotic proteins. ...

        Research

        Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors

        Early changes in cell morphology upon treatments are a strong indication that the inhibitor is directly targeting tubulin ...

        Research

        In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma

        Ependymomas (EPN) are the third most common malignant brain cancer in children. Treatment strategies for pediatric EPN have remained unchanged over recent decades, with 10-year survival rates stagnating at just 67% for children aged 0-14 years. Moreover, a proportion of patients who survive treatment often suffer long-term neurological side effects as a result of therapy. It is evident that there is a need for safer, more effective treatments for pediatric EPN patients. ...

        Research

        MK2 inhibition induces p53-dependent senescence in glioblastoma cells

        In response to DNA damaging chemotherapy, targeting MK2 in p53-mutated cells produces a phenotype that is distinct from the p53-deficient phenotype ...

        Research

        Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model

        Acute megakaryoblastic leukemia of Down syndrome (DS-AMKL) is a model of clonal evolution from a preleukemic transient myeloproliferative disorder requiring both a trisomy 21 (T21) and a GATA1s mutation to a leukemia driven by additional driver mutations. ...

        Page 12 of 57